Mometasone Furoate Market, by Dosage Form (Nasal Spray, Cream, Ointment, Inhalers, Others), by Indication (Inflammatory Skin Disorders, Asthma, Allergic Rhinitis, Others), by Route Of Administration (Nasal Administration, Topical, Oral) , by Distribution

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	193 Pages	Coherent Market Insights	September, 2022	CMI17440697

Best Price Guarantee
Price	from $4,500
Length	193 Pages
Publisher	Coherent Market Insights
Published Date	September, 2022
SKU	CMI17440697

Mometasone Furoate Market, by Dosage Form (Nasal Spray, Cream, Ointment, Inhalers, Others), by Indication (Inflammatory Skin Disorders, Asthma, Allergic Rhinitis, Others), by Route Of Administration (Nasal Administration, Topical, Oral) , by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, And Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Mometasone furoate topical is effective at reducing the redness, itching, swelling, and other pain caused by several skin conditions. Mometasone furoate is a corticosteroid drug also used to treat asthma and it is an effective treatment for a variety of skin allergies as well as other allergic conditions like hay fever and allergic rhinitis.

Market Dynamics

Increasing prevalence of asthma worldwide is expected to witness significant growth in forecast period. For instance, according to the World Health Organization (WHO), in 2019, 455 000 individuals died from asthma and an estimated 262 million people were affected by asthma worldwide. Asthma is widely misdiagnosed and poorly managed, particularly in low- and middle-income countries. In most severe cases, asthma can be fatal.

Increasing product launches and approvals by market players are expected to drive growth of the global mometasone furoate market over the forecast period. For instance, in April 2017, Amneal Pharmaceuticals LLC, a U.S.-based, publicly traded generics and specialty pharmaceutical company launched Mometasone furoate nasal spray, the first pharmaceutical product that Amneal Pharmaceuticals LLC had produced in spray form. Nasonex is therapeutic equivalent of mometasone furoate and is offered in 50 mcg/spray strength.

Increasing research and development activities related to mometasone furoate are expected to drive growth of market over the forecast period. For instance, according to an article published in Medicine, medical journal, in December 2019, a study was performed on patients with head and neck squamous cell carcinoma (HNSCC) to check efficacy of local application of mometasone furoate in reducing acute radiation dermatitis (ARD) in China. Patients were divided into two groups, test groups and control groups. The patients in test groups were given mometasone furoate once daily from the start of their radiotherapy until the test side skin acquired ARD lesions, and patients in control groups, were given no treatment at all. The study showed that, mometasone furoate inunction after high dose radiotherapy can prevent acute radiation dermatitis (ARD).

Key features of the study:

This report provides an in-depth analysis of the global mometasone furoate market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global mometasone furoate market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include include Cipla, Teva Pharmaceuticals, Glenmark Pharmaceuticals, AdvaCare Pharma, Medlab Pharmaceuticals Private Limited, Dermocare Laboratories, Iva Healthcare Private Limited, Unilab Chemicals & Pharmaceuticals Pvt Ltd, Organon group of companies, Cosette Pharmaceuticals, Taro Pharmaceutical Industries Ltd., and Hikma Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
The global mometasone furoate market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global mometasone furoate market

Detailed Segmentation:

Global Mometasone Furoate Market, By Dosage form:
Nasal Spray
Cream
Ointment
Inhalers
Others (Topical Solutions, etc.)
Global Mometasone Furoate Market, By Indication:
Inflammatory Skin Disorders
Asthma
Allergic rhinitis
Others (Hay Fever, etc.)
Global Mometasone Furoate Market, By Route of Administration:
Nasal Administration
Topical
Oral
Global Mometasone Furoate Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Mometasone Furoate Market, By Region:
North America
By Country:
U.S.
Canada
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Country:
GCC
Israel
Rest of Middle East
Africa
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Cipla *
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Teva Pharmaceuticals
Glenmark Pharmaceuticals
AdvaCare Pharma
Medlab Pharmaceuticals Private Limited
Dermocare Laboratories
Iva Healthcare Private Limited
Unilab Chemicals & Pharmaceuticals Pvt Ltd
Organon group of companies
Cosette Pharmaceuticals
Taro Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals.

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Overview: Report Description; Market Definition and Scope; Executive Summary; Market Snippet, By Dosage form; Market Snippet, By Indication; Market Snippet, By Route of Administration; Market Snippet, By Distribution Channel; Market Snippet, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Opportunities; Impact Analysis; Porter’s Analysis; Industry Trends; Key Highlights; Epidemiology; Reimbursement Scenario; Regulatory Scenario; Product Launch and Approvals; Acquisition and Collaboration Scenario
4. Global Mometasone Furoate Market - Impact of Coronavirus (Covid-19) Pandemic: COVID-19 Epidemiology; Impact of COVID-19 on Demand and Supply of Mometasone furoate; Impact of COVID-19 on the Overall Healthcare Sector
5. Global Mometasone Furoate Market , By Dosage Form, 2017-2030 (US$ Million): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017-2030; Segment Trends; Nasal spray; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Cream; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Ointment; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Inhalers; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
6. Global Mometasone Furoate Market , By Indication, 2017-2030 (US$ Million): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017-2030; Segment Trends; Inflammatory skin disorders; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Asthma; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Allergic rhinitis; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
7. Global Mometasone Furoate Market , By Route of Administration , 2017-2030 (US$ Million): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017-2030; Segment Trends; Nasal; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Topical; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Oral; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
8. Global Mometasone Furoate Market , By Distribution Channel, 2017-2030 (US$ Million): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017-2030; Segment Trends; Hospitals Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Retail Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Online Pharmacies; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
9. Global Mometasone Furoate Market , By Region, 2017-2030 (US$ Million): Introduction; Market Share Analysis, By Region, 2022 and 2030 (%); Y-o-Y Growth Analysis, For Regions, 2017-2030; Regional Trends; North America; Market Size and Forecast, By Dosage Form, 2017-2030 (US$ Mn); Market Size and Forecast, By Indication, 2017-2030 (US$ Mn); Market Size and Forecast, By Route of Administration, 2017-2030 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn); Market Size and Forecast, By Country, 2017-2030 (US$ Mn); U.S.; Canada; Latin America; Market Size and Forecast, By Dosage Form, 2017-2030 (US$ Mn); Market Size and Forecast, By Indication, 2017-2030 (US$ Mn); Market Size and Forecast, By Route of Administration, 2017-2030 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn); Market Size and Forecast, By Country, 2017-2030 (US$ Mn); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Market Size and Forecast, By Dosage Form, 2017-2030 (US$ Mn); Market Size and Forecast, By Indication, 2017-2030 (US$ Mn); Market Size and Forecast, By Route of Administration, 2017-2030 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn); Market Size and Forecast, By Country, 2017-2030 (US$ Mn); Germany; U.K.; France; Italy; Spain; Russia; Rest of Europe; Asia Pacific; Market Size and Forecast, By Dosage Form, 2017-2030 (US$ Mn); Market Size and Forecast, By Indication, 2017-2030 (US$ Mn); Market Size and Forecast, By Route of Administration, 2017-2030 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn); Market Size and Forecast, By Country, 2017-2030 (US$ Mn); China; India; Japan; Australia; South Korea; ASEAN; Rest of Asia Pacific; Middle East; Market Size and Forecast, By Dosage Form, 2017-2030 (US$ Mn); Market Size and Forecast, By Indication, 2017-2030 (US$ Mn); Market Size and Forecast, By Route of Administration, 2017-2030 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn); Market Size and Forecast, By Country, 2017-2030 (US$ Mn); GCC; Israel; Rest of Middle East; Africa; Market Size and Forecast, By Dosage Form, 2017-2030 (US$ Mn); Market Size and Forecast, By Indication, 2017-2030 (US$ Mn); Market Size and Forecast, By Route of Administration, 2017-2030 (US$ Mn); Market Size and Forecast, By Distribution Channel, 2017-2030 (US$ Mn); Market Size and Forecast, By Country/Region, 2017-2030 (US$ Mn); South Africa; Central Africa; North Africa
10. Competitive Landscape: Company Profiles; Cipla.*; Company Overview; Product Portfolio; Financial Performance; Recent Developments/Updates; Strategies; Teva Pharmaceuticals; Glenmark Pharmaceuticals; AdvaCare Pharma; Medlab Pharmaceuticals Private Limited; Dermocare Laboratories; Iva Healthcare Private Limited; Unilab Chemicals & Pharmaceuticals Pvt Ltd; Organon group of companies; Cosette Pharmaceuticals; Taro Pharmaceutical Industries Ltd.; Hikma Pharmaceuticals.; *Key pointers provided are also applicable to other companies covered in the scope of the report.; Analyst Views
11. Section: Research Methodology; About us; Contact; *Browse 33 market data tables and 25 figures on “Mometasone Furoate Market” - Global Forecast to 2030.